At Peptides Unleashed, in this article focuses on a highly requested topic, a detailed Tirzepatide and Mazdutide comparison.
These two advanced metabolic medications Tirzepatide and Mazdutide are redefining modern obesity treatment. They both work through dual hormonal pathways yet the second receptor each drug targets leads to noticeably different metabolic effects.
- Tirzepatide combines GIP and GLP-1 activation
- Mazdutide combines Glucagon and GLP-1 activation
Both reduce appetite and support weight loss but their secondary pathways give each drug a unique profile especially in areas like energy expenditure, liver fat reduction, and blood sugar improvement.
Tirzepatide was FDA approved across multiple global markets beginning in 2022.
Mazdutide became the first-ever GLP-1/glucagon dual agonist to receive regulatory approval in June 2025 (China only).
If you’re trying to understand which option makes more sense for specific patient groups this breakdown gives you the practical evidence based clarity you need.
How Each Medication Works Inside the Body
Tirzepatide: Dual GIP + GLP-1 Activation
Tirzepatide binds to both GLP-1 and GIP receptors with a stronger affinity toward GIP activation. This pairing helps lower appetite, control blood sugar, and enhance insulin response.
Research shows tirzepatide also boosts adiponectin levels a hormone that improves fat metabolism and insulin sensitivity.
Mazdutide: GLP-1 + Glucagon Activation
Mazdutide follows a different strategy. While GLP-1 suppresses appetite, the glucagon pathway increases energy expenditure encourages fat oxidation, and improves metabolic flexibility.
Mazdutide uses an estimated 8:1 activation ratio favoring GLP-1. This ensures glucose control remains stable, while glucagon effects primarily drive metabolic and liver fat improvements.
Weight Loss Outcomes: Which One Works Best?
Tirzepatide Results (72 Weeks)
(SURMOUNT-1 Trial)
- 5 mg → 15.0% loss
- 10 mg → 19.5% loss
- 15 mg → 20.9% loss
More than 63% of the highest-dose group lost ≥20% of their body weight.
Mazdutide Results (48 Weeks)
(GLORY-1 Phase 3)
- 4 mg → 12.05% loss
- 6 mg → 14.84% loss
Nearly 50% of participants on 6 mg achieved ≥15% weight loss despite the shorter duration.
Mazdutide and Tirzepatide Comparison Snapshot
| Feature | Tirzepatide | Mazdutide |
|---|---|---|
| Receptors | GIP + GLP-1 | Glucagon + GLP-1 |
| Typical weight loss | 15–21% (72+ weeks) | 12–15% (48 weeks) |
| Waist reduction | ~9.5 cm | ~10.7 cm |
| Liver fat reduction | Moderate | Up to 80% |
| Global availability | Yes | Only China |
Quick verdict:
Tirzepatide reaches slightly higher long-term weight-loss peaks.
Mazdutide outperforms in liver fat reduction and metabolic flexibility.
Blood Sugar Control: Both Effective, But
Tirzepatide for Glycemic Improvement
Clinical trials show:
- Up to 2.24% reduction in HbA1c
- 91–97% of patients hit HbA1c <7% treatment goals
- Major improvements in fasting glucose
Mazdutide for Type 2 Diabetes
(DREAMS-1 Trial)
- 4 mg → 1.57% HbA1c drop
- 6 mg → 2.15% HbA1c drop
Glucagon pathway does not cause hyperglycemia due to the built-in GLP-1 dominance.
Bottom line:
Both drugs strongly improve glycemic control. Tirzepatide has larger and more global clinical datasets, but mazdutide’s results are compelling—especially considering trial populations with high visceral fat.
Liver Fat Reduction: Mazdutide Dominates
Mazdutide’s glucagon activation gives it a powerful advantage for fatty liver disease.
Mazdutide Trial Findings
- 80.2% reduction in liver fat after 48 weeks
- 73.3% reduction seen in earlier trials
- Particularly effective for MAFLD (very common in Asian populations)
Source: Ji et al., 2025; Ji et al., 2023.
Tirzepatide’s Liver Benefits
It improves liver markers, but reductions in fat content are not as dramatic as those seen with mazdutide.
Side Effects: Similar Class Effects, Mild to Moderate
Most Common Issues (Both Drugs)
- Nausea
- Diarrhea
- Vomiting
- Reduced appetite
- Constipation
Most symptoms appear during dose escalation and taper off over time.
Discontinuation rates remain below 5%.
Serious Risks to Consider
Tirzepatide carries additional FDA-required warnings:
- Thyroid C-cell tumor risk (based on rodent data)
- Gallbladder issues
- Acute pancreatitis
- Kidney injury (secondary to dehydration risks)
Mazdutide’s trials showed very low serious adverse event rates.
Sources: Aronne et al., 2024.
What Happens If You Stop Treatment?
Stopping these medications almost always leads to significant weight regain because obesity is a chronic condition.
Tirzepatide Withdrawal Data
(SURMOUNT-4)
- After stopping: 14% regained
- Continuing treatment: maintained nearly all progress
- Real-world 26-week China follow-up showed 9–12% regain
Even after regain, most participants remained below baseline weight.
Sources: Aronne et al., 2024; Chen et al., 2025.
Conclusion:
These drugs are long-term therapies, not short-term fixes.
Who Should Consider Tirzepatide?
Best fit for:
- Those wanting the maximum possible weight loss
- Patients needing treatment outside China
- Individuals requiring extensive safety and cardiovascular outcome data
- People with type 2 diabetes or heart failure with preserved ejection fraction
- Anyone seeking a globally approved medication
Who Should Consider Mazdutide?
Best fit for:
- People with fatty liver disease (MAFLD/MASH)
- Asian populations with high visceral fat at lower BMI levels
- Individuals who need stronger effects on energy expenditure, not just appetite
- Patients located in China (only approved market so far)
- Those who did not respond well to GIP/GLP-1 drugs like tirzepatide
How Do These Compare to Semaglutide, Retatrutide & Other Agents?
Tirzepatide vs Semaglutide
A 2025 NEJM study found:
- Tirzepatide: 20.2% loss
- Semaglutide 2.4 mg: 13.7% loss
- Tirzepatide produced 47% greater relative weight loss
Source: Aronne et al., 2025.
Triple-Agonist Retatrutide
Retatrutide activates GIP + GLP-1 + glucagon simultaneously.
- 24.2% weight loss at 48 weeks
- Massive metabolic improvements
- More research needed on long-term safety
Other GLP-1/Glucagon Drugs
Survodutide, Pemvidutide, and Cotadutide are in earlier or mid-stage development, with Survodutide showing the strongest results so far.
Source: Mikhail et al., 2024.
Mazdutide and Tirzepatide Comparison: Which One Is “Better”?
There is no universal winner here. Each drug excels in different areas.
Choose Tirzepatide if you want:
- The highest documented long-term weight loss
- Extensive global safety data
- A treatment available outside China
- Strong diabetes and cardiovascular benefits
Choose Mazdutide if you want:
- Dramatic improvement in liver fat reduction
- Better metabolic benefits for Asian body profiles
- Added fat-burning from increased energy expenditure
- Access within China where it is approved
Both medications represent a major leap forward in obesity and metabolic disease care—and ongoing research will continue shaping how each is used across different populations.
References
All citations below are from peer-reviewed studies and clinical trials referenced in this rewrite:
- Willard, F. S., et al. (2020). JCI Insight. https://doi.org/10.1172/jci.insight.140532
- Thomas, M. K., et al. (2020). The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa863
- Ji, L., et al. (2023). Nature Communications. https://doi.org/10.1038/s41467-023-44067-4
- Li, Y., et al. (2023). Proceedings of the National Academy of Sciences (PNAS). https://doi.org/10.1073/pnas.2303696120
- Cecot, J., et al. (2024). Biomedical and Pharmacology Journal. https://doi.org/10.35630/2024/14/4.412
- Fanshier, A. V., et al. (2023). Clinical Diabetes. https://doi.org/10.2337/cd22-0060
- Ji, L., et al. (2025). The New England Journal of Medicine. https://doi.org/10.1056/nejmoa2411528
- Yang, J., et al. (2024). Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1453825
- Zhu, D., et al. (2025). Diabetes. https://doi.org/10.2337/db25-306-or
- Aronne, L. J., et al. (2024). JAMA. https://doi.org/10.1001/jama.2023.24945
- Chen, C., et al. (2025). Life Metabolism. https://doi.org/10.1093/lifemeta/loaf024
- Aronne, L. J., et al. (2025). The New England Journal of Medicine. https://doi.org/10.1056/nejmoa2416394
- Sanyal, A. J., et al. (2024). Nature Medicine. https://doi.org/10.1038/s41591-024-03018-2
- Son, J. W., et al. (2025). Endocrine Reviews. https://doi.org/10.1210/endrev/bnaf036
- Mikhail, N. (2024). Journal of Diabetes & Metabolic Disorders. https://doi.org/10.31579/2640-1045/184
